Due to health issues, this site is no longer maintained and will be shut down shortly.

XBIOW Xenetic Biosciences, Inc. - Warrants

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progestin resistant endometrial cancer. It is also developing ErepoXen, a drug using PolyXen platform technology for the treatment of anemia in chronic kidney disease patients. The company has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.  This security was issued by Xenetic Biosciences, Inc., whose common stock symbol is XBIO.

$0.85  +0.12 (15.81%)
As of 03/09/2023 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Warrants
Category3:  Operating Companies
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  07/23/2019
Outstanding shares:  15,166,596
Average volume:  528
Market cap:   $6,369,970
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy